Glycomimetics INC Form 4 insider transactions

Fairmount Funds Management LLC and 3 others reported changes in beneficial ownership of Glycomimetics Inc common stock on July 16, 2026.

Crescent Biopharma, Inc. director Jonathan Violin was granted 11,050 stock options as part of his compensation package.

Director David Charles Lubner was granted 11,050 stock options in Crescent Biopharma, Inc. as part of his compensation.

Director Alexandra Balcom was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity incentive.

Director Susan Moran was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity compensation arrangement.

Fairmount Funds Management and associated directors were granted 11,050 stock options in Crescent Biopharma, Inc.

Crescent Biopharma's Chief Scientific Officer, Jan Pinkas, was granted 22,507 Restricted Stock Units and options to purchase 70,025 ordinary shares.

Crescent Biopharma's Chief Business Officer, Christopher Doughty, received significant equity awards including Restricted Stock Units and stock options, aligning his interests with long-term company performance.

Crescent Biopharma's CEO, Joshua T. Brumm, received significant equity awards including Restricted Stock Units and stock options, vesting over several years.

Crescent Biopharma's Chief Financial Officer, Richard William Scalzo, received significant equity awards including Restricted Stock Units and stock options.

Crescent BioPharma's President and COO, Jonathan McNeill, reported the acquisition of 25,507 Restricted Stock Units and options for 78,029 ordinary shares.

Crescent Biopharma's Chief Medical Officer, Ellie Eunkyung Im, received significant equity awards including Restricted Stock Units and stock options.

Crescent Biopharma's Treasurer, SVP of Finance, and Chief Accounting Officer, Ryan Lynch, received significant equity awards including Restricted Stock Units and stock options.

Crescent BioPharma's General Counsel, Barbara Harlin Bispham, received significant equity awards including RSUs and stock options, aligning her interests with long-term company performance.

Crescent BioPharma's President and COO, Jonathan McNeill, was granted 172,836 stock options with an exercise price of $13.17, vesting over 48 months.

Crescent Biopharma's CEO, Joshua T. Brumm, was granted 345,672 stock options with an exercise price of $13.17, vesting over 48 months.

Fairmount Funds Management and related entities increased their beneficial ownership in Crescent Biopharma, acquiring ordinary shares and pre-funded warrants.

Crescent Biopharma, Inc. has granted 142,474 stock options to its Chief Scientific Officer, Jan Pinkas, with an exercise price of $13.14 per share.

GlycoMimetics Inc. Director Susan Moran was granted 9,023 stock options with an exercise price of $15.3 per share, vesting over approximately one year.

Fairmount Funds Management LLC, a 10% owner and director of Glycomimetics Inc., reported the acquisition of 9,023 stock options with an exercise price of $15.30, vesting by June 2026.

GlycoMimetics Inc. Director Jonathan Violin was granted 9,023 stock options with an exercise price of $15.30, vesting based on continued service.

GlycoMimetics Inc. Director Alexandra Balcom was granted 9,023 stock options with an exercise price of $15.30, vesting on the earlier of June 23, 2026, or the next annual meeting.

GlycoMimetics Inc. Director and 10% Owner David Charles Lubner was granted 9,023 stock options with an exercise price of $15.30, aligning his interests with shareholders.

A group of investment funds led by BVF Partners L.P. has reported a substantial increase in their beneficial ownership of GlycoMimetics Inc. common stock and pre-funded warrants following the completion of a reverse merger with Crescent Biopharma, Inc.

GlycoMimetics, Inc. provides supplemental disclosures regarding its previously announced reverse merger with Crescent Biopharma, Inc., detailing the strategic rationale, valuation terms, and a significant concurrent PIPE financing.

GlycoMimetics, Inc. announced that its acquisition target, Crescent Biopharma, Inc., will present at the Jefferies Global Healthcare Conference as the companies anticipate closing their merger in Q2 2025.

GlycoMimetics, Inc. amends its merger agreement with Crescent Biopharma, Inc. to clarify the treatment of restricted stock units and voting mechanics, with GlycoMimetics securityholders expected to own approximately 2.6% of the combined company post-merger.

Crescent Biopharma appoints David Lubner, a seasoned finance executive, to its board of directors as the company prepares for its acquisition by GlycoMimetics.

Crescent Biopharma announces key leadership appointments, including Joshua Brumm as CEO, to advance its pipeline of oncology therapeutics, with an IND submission for its lead program expected in Q4 2025.

GlycoMimetics, Inc. and Crescent Biopharma, Inc. are set to merge, focusing on advancing Crescent's oncology programs, particularly its novel PD-1 x VEGF bispecific antibody, CR-001.